Cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil (5-FU) in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R&M SCCHN) (EXTREME).

被引：0
|
作者：
Vermorken, J. B.
Mesia, R.
Vega-Villegas, M. E.
Remenar, E.
Hitt, R.
Kawecki, A.
Rottey, S.
Zabolotnyy, D.
Erfan, J.
Amellal, N.
Antwerpen, U. Z.
机构：
[1] UZ Antwerpen, Edegem, Belgium
[2] Hosp Duran I Reynals Inst Catala Oncol, Barcelona, Spain
[3] Hosp Univ Marques Valdecilla, Santander, Spain
[4] Orszagos Onkol Intezet, Budapest, Hungary
[5] Hosp 12 Octubre, E-28041 Madrid, Spain
[6] Klin Nowotworow Glowy & Szyi, Warsaw, Poland
[7] UZ Gent, Ghent, Belgium
[8] Inst Otolaringol AMS Ukraine, Kiev, Ukraine
[9] Szalbolcs Szatmar Bereg Megyei Josa Andras Korhaz, Nyiregyhaza, Hungary
[10] Merck KGaA, Darmstadt, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：289S / 289S
页数：1
相关论文
共 50 条
  • [21] Weekly paclitaxel, carboplatin and cetuximab (PCC) as first-line treatment of recurrent and/or metastatic head & neck squamous cell carcinoma (R/M-HNSCC) for patients ineligible to cisplatin based chemotherapy
    Carinato, H.
    Burgy, M.
    Fischbach, C.
    Kalish-Weindling, M.
    Pabst, L.
    Frasie, V.
    Thiery, A.
    Coliat, P.
    Demarchi, M. F.
    Petit, T.
    Borel, C.
    ANNALS OF ONCOLOGY, 2020, 31 : S668 - S668
  • [22] SAFETY AND EFFICACY OF CISPLATIN PLUS 5-FU AND CETUXIMAB IN HPV-POSITIVE AND HPV-NEGATIVE RECURRENT AND/OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (R/M SCCHN): ANALYSIS OF THE PHASE III EXTREME TRIAL
    Psyrri, A.
    Licitra, L.
    De Blas, B.
    Celik, I.
    Vermorken, J. B.
    ANNALS OF ONCOLOGY, 2012, 23 : 334 - 335
  • [23] A phase II study of vinorelbine GIRL), cisplatin (CDDP) and 5-Fluorouracil (FU) in patients (PTS) with locally advanced recurrent, and/or metastatic squamous cell carcinoma of the head and neck (SCCHN)
    Guillem, V
    Muñoz, MA
    Yaya, R
    Soriano, V
    Climent, MA
    Gaspar, C
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S176 - S176
  • [24] Cetuximab in combination with irinotecan/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFIRI) in the first-line treatment of metastatic colorectal cancer (mCRC)
    Peeters, M.
    Raoul, J.-L.
    Van Laethem, J.-L.
    Rougier, P.
    Brezault, C.
    Husseini, F.
    Cals, L.
    Zubel, A.
    Vedovato, J.-C.
    EJC SUPPLEMENTS, 2005, 3 (02): : 188 - 188
  • [25] Cetuximab with or without sorafenib in recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN)
    Gilbert, Jill
    Schell, Michael J.
    Zhao, Xiuhua
    Murphy, Barbara A.
    Tanvetyanon, Tawee
    Hayes, David N.
    Haigentz, Missak
    Saba, Nabil F.
    Nieva, Jorge J.
    Perez, Jimena
    Bishop, Justin A.
    Chung, Christine H.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [26] Treatment of recurrent and/or metastatic squamous cell head and neck carcinoma with a combination of vinorelbine, cisplatin, and 5-fluorouracil: A multicenter phase II trial
    Gebbia, V
    Mantovani, G
    Agostara, B
    Contu, A
    Farris, A
    Colucci, G
    Cognetti, F
    Restivo, G
    Speciale, R
    Ferrero, B
    Testa, A
    Curreli, L
    Cardinale, A
    Bajetta, E
    Gebbia, N
    ANNALS OF ONCOLOGY, 1995, 6 (10) : 987 - 991
  • [27] TREATMENT OF RECURRENT SQUAMOUS-CELL CARCINOMA (RSCCHN) OF HEAD AND NECK WITH A SEQUENTIAL METHOTREXATE (MTX) 5-FLUOROURACIL (5-FU) REGIMEN
    SCHERLACHER, A
    JAKSE, R
    LEHNERT, M
    LARYNGOLOGIE RHINOLOGIE OTOLOGIE VEREINIGT MIT MONATSSCHRIFT FUR OHRENHEILKUNDE, 1985, 64 (02): : 58 - 61
  • [28] Paclitaxel, cisplatin, and 5-fluorouracil for patients with advanced or recurrent squamous cell carcinoma of the head and neck
    Hussain, M
    Gadgeel, S
    Kucuk, O
    Du, W
    Salwen, W
    Ensley, J
    CANCER, 1999, 86 (11) : 2364 - 2369
  • [29] Cetuximab, docetaxel, and cisplatin (TPEx) as first-line treatment in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): First results of phase II trial GORTEC 2008-03.
    Guigay, J.
    Fayette, J.
    Dillies, A.
    Sire, C.
    Kerger, J. N.
    Tennevet, I.
    Machiels, J. H.
    Zanetta, S.
    Pointreau, Y.
    Le Moal, L. Bozec
    Ribere, L. Brugel
    Henry, S.
    Temam, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [30] RESULTS OF TPEX (DOCETAXEL, CISPLATIN, CETUXIMAB) REGIMEN USE IN FIRST LINE PATIENTS WITH RECURRENT/METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (R/M SCCHN) IN A SINGLE INSTITUTION
    Even, C.
    Bobillot, B.
    Mayache-Badis, L.
    Ferrand, F. R.
    Lezghed, N.
    Bidault, F.
    Auperin, A.
    Temam, S.
    Janot, F.
    Schilf, A.
    Guigay, J.
    ANNALS OF ONCOLOGY, 2014, 25
12345